Justin W Ady1, Clark Johnsen1, Kelly Mojica1, Jacqueline Heffner1, Damon Love1, Amudhan Pugalenthi1, Laurence J Belin1, Nanhai G Chen2, Yong A Yu3, Aladar A Szalay4, Yuman Fong5. 1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. 2. Genelux Corporation, San Diego Science Center, San Diego, CA; Department of Radiation Medicine and Applied Sciences, Rebecca & John Moores Comprehensive Cancer Center, University of California, San Diego, CA. 3. Genelux Corporation, San Diego Science Center, San Diego, CA. 4. Genelux Corporation, San Diego Science Center, San Diego, CA; Department of Radiation Medicine and Applied Sciences, Rebecca & John Moores Comprehensive Cancer Center, University of California, San Diego, CA; Department of Biochemistry, Rudolph Virchow Center for Experimental Biomedicine, and Institute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany. 5. Department of Surgery, City of Hope Medical Center, Duarte, CA. Electronic address: yfong@COH.org.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) commonly presents at a late stage when surgery is no longer a curative option. As such, novel therapies for advanced HCC are needed. Oncolytic viruses are a viable option for cancer therapy owing to their ability to specifically infect, replicate within, and kill cancer cells. In this study, we have investigated the ability of GLV-2b372, a novel light-emitting recombinant vaccinia virus derived from a wild-type Lister strain, to kill HCC. METHODS: Four human HCC cell lines were assayed in vitro for infectivity and cytotoxicity. Viral replication was quantified via standard viral plaque assays. Flank HCC xenografts generated in athymic nude mice were treated with intratumoral GLV-2b372 to assess for tumor growth inhibition and viral biodistribution. RESULTS: Infectivity occurred in a time- and concentration-dependent manner with 70% cell death in all cell lines by day 5. All cell lines supported efficient viral replication. At 25 days after infection, flank tumor volumes decreased by 50% whereas controls increased by 400%. Tumor tissue demonstrated substantial GLV-2b372 infection at 24 hours, 48 hours, and 2 weeks. CONCLUSION: We demonstrate that GLV-2b372 efficiently kills human HCC in vitro and in vivo and is a viable treatment option for patients with HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) commonly presents at a late stage when surgery is no longer a curative option. As such, novel therapies for advanced HCC are needed. Oncolytic viruses are a viable option for cancer therapy owing to their ability to specifically infect, replicate within, and kill cancer cells. In this study, we have investigated the ability of GLV-2b372, a novel light-emitting recombinant vaccinia virus derived from a wild-type Lister strain, to kill HCC. METHODS: Four humanHCC cell lines were assayed in vitro for infectivity and cytotoxicity. Viral replication was quantified via standard viral plaque assays. Flank HCC xenografts generated in athymic nude mice were treated with intratumoral GLV-2b372 to assess for tumor growth inhibition and viral biodistribution. RESULTS: Infectivity occurred in a time- and concentration-dependent manner with 70% cell death in all cell lines by day 5. All cell lines supported efficient viral replication. At 25 days after infection, flank tumor volumes decreased by 50% whereas controls increased by 400%. Tumor tissue demonstrated substantial GLV-2b372infection at 24 hours, 48 hours, and 2 weeks. CONCLUSION: We demonstrate that GLV-2b372 efficiently kills humanHCC in vitro and in vivo and is a viable treatment option for patients with HCC.
Authors: Sunil J Advani; Lisa Buckel; Nanhai G Chen; Daniel J Scanderbeg; Ulrike Geissinger; Qian Zhang; Yong A Yu; Richard J Aguilar; Arno J Mundt; Aladar A Szalay Journal: Clin Cancer Res Date: 2012-02-29 Impact factor: 12.531
Authors: Boris Blechacz; Patrick L Splinter; Suzanne Greiner; Rae Myers; Kah-Whye Peng; Mark J Federspiel; Stephen J Russell; Nicholas F LaRusso Journal: Hepatology Date: 2006-12 Impact factor: 17.425
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Ivaylo Gentschev; Meike Müller; Marion Adelfinger; Stephanie Weibel; Friedrich Grummt; Martina Zimmermann; Michael Bitzer; Martin Heisig; Qian Zhang; Yong A Yu; Nanhai G Chen; Jochen Stritzker; Ulrich M Lauer; Aladar A Szalay Journal: PLoS One Date: 2011-07-11 Impact factor: 3.240
Authors: R J S Coelen; M J de Keijzer; R Weijer; V V Loukachov; J K Wiggers; F P J Mul; A C W A van Wijk; Y Fong; M Heger; T M van Gulik Journal: Cancer Gene Ther Date: 2017-04-14 Impact factor: 5.987
Authors: Abdellatif Bouazzaoui; Ahmed A H Abdellatif; Faisal A Al-Allaf; Neda M Bogari; Saied Al-Dehlawi; Sameer H Qari Journal: Pharmaceutics Date: 2021-01-22 Impact factor: 6.321